Canopy Growth Corporation

NASDAQ:CGC

Drug Manufacturers - Specialty & Generic

Healthcare
$0.50 +1.07%

+$0.01 today

Market cap
$212.31M
Beta
0.78
P/E (TTM)
-1.8
EPS (TTM)
-$0.76
52W Low $0.84High $2.38

Volume 3.44M

Average 9.97M

CGC Income Before Tax

Profit after all operating and non-operating items but before income tax.

Canopy Growth CorporationNASDAQ: CGC

Income Before Tax · Q4 FY2025 · quarter ended Mar 2026

Income before tax remains negative

Q4 FY2025 income before tax was -CA$157.97M, compared with -CA$221.17M a year earlier. Trailing-twelve-month income before tax was -CA$286.05M.

Context

  • Income before tax amounted to 54.4% of revenue in FY2025, down 167.6 pp from a year earlier.
  • Income before tax grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -CA$157.97M or moves back toward the trailing-twelve-month quarterly average of -CA$71.51M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-CA$157.97M-84.9% QoQ
Last fiscal yearMar 2026
-CA$262.89M+56.0% YoY
LTMMar 2026
-CA$286.05M+52.1% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+28.6%——
1 year+56.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

CAD · from the income statement

Latest · FY2025
(262.89M) CAD
Year-over-year change
+56.0%

Income Before Tax vs competitors

How CGC compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +52.1% is the 3rd highest of 9, against a peer median of +26.5%.
  • Income before tax amounts to 91.6% of revenue for CGC, versus a peer median of 73.9%.
CGC Competitors
Income Before Tax for CGC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IRWDIronwood Pharmaceuticals, Inc.LTM Mar 2026$171.47M USD+615.4%-34.8%47.4%
ACBAurora Cannabis Inc.LTM Mar 2026-CA$5.04M CAD-124.7%—1.6%
TKNOAlpha Teknova, Inc.LTM Mar 2026-$17.09M USD+26.7%—40.9%
LFCRLifecore Biomedical, Inc.LTM Mar 2026-$33.68M USD——24.9%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-$69.66M USD+46.5%—832.6%
BIOABioAge Labs, Inc.LTM Mar 2026-$89.93M USD-26.6%—871.8%
CABACabaletta Bio, Inc.LTM Mar 2026-$175.43M USD-38.4%——
DHDefinitive Healthcare Corp.LTM Mar 2026-$239.07M USD+69.6%—100.3%
LYELLyell Immunopharma, Inc.LTM Mar 2026-$246.41M USD+26.3%—794858.1%
CGCCanopy Growth CorporationLTM Mar 2026-CA$286.05M CAD+52.1%—91.6%
Peer median (excluding CGC) —+26.5%-34.8%73.9%

Competitors are the stored peer set for CGC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Mar 2022
FY2022
Mar 2023
FY2023
Mar 2024
FY2024
Mar 2025
FY2025
Mar 2026
Revenue475.7M333.25M297.15M269M483.67M
Cost of Revenue663.11M396.78M216.26M189.48M386.51M
Gross Profit(187.41M)(63.53M)80.88M79.51M97.16M
Gross Margin-39.4%-19.1%27.2%29.6%20.1%
Research & Development32.26M21.72M4.61M1.91M0
Selling, General & Admin361.1M297.98M180.59M121.71M223.11M
Operating Expenses831.39M2.57B309.6M196.65M322.6M
Depreciation & Amortization110.94M80.03M53.18M43.12M50.86M
EBITDA(52.98M)(2.88B)(312.83M)(479.31M)50.86M
EBITDA Margin-11.1%-864.2%-105.3%-178.2%10.5%
Operating Income(1.02B)(2.63B)(228.71M)(117.14M)(161.66M)
Operating Margin-214.2%-789.3%-77.0%-43.5%-33.4%
Interest Income6.6M24.28M16.24M8.82M10M
Interest Expense103.94M126.16M105.35M74.57M38.19M
Other Income / Expenses750.94M(455.64M)(242.64M)(479.85M)(101.23M)
Income Before Tax(267.86M)(3.09B)(471.36M)(597M)(262.89M)
Pre-Tax Margin-56.3%-926.1%-158.6%-221.9%-54.4%
Income Tax Expense(8.95M)(5.73M)12.33M7.14M23K
Net Income(310.04M)(3.28B)(657.27M)(598.12M)(366.64M)
Net Margin-65.2%-983.7%-221.2%-222.4%-75.8%
EPS (Basic)(7.70)(70.70)(6.47)(5.53)(0.88)
EPS (Diluted)(7.70)(70.70)(8.79)(5.53)(0.88)
Weighted Avg Shares39.13M46.37M101.63M107.55M2.98B
Weighted Avg Shares (Diluted)39.13M46.37M74.79M107.55M2.98B

Canopy Growth Corporation

NASDAQ:CGC

Intrinsic Alpha fair value

Locked

Current Price

$0.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.